FIRST Trial

FIrst-line Rituximab in Systemic lupus erythematosus Trial

The Trial

FIRST is a multicentre, double-blind, randomised, placebo-controlled, superiority trial with an internal pilot and cost effectiveness analysis to determine if early treatment with rituximab in moderate/severe lupus is superior to usual care.

Trial Updates

Number of participants recruited: XX/128

Number of trial locations open to recruitment:

Open trial locations

[Trial Location name]

[Trial Location name]

[Trial Location name]

Last updated: mm/yyyy

Trial Locations

[Insert google map link with pins for trial locations]